GSK plc vs Global X Defense Tech ETF — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Global X Defense Tech ETF trades at $70.12. The key difference: GSK plc pays a 3.57% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals.
| GSK | SHLD | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $78.02 |
52-Week Low | $38.22 | $58.20 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SHLD, the Global X Defense Tech ETF, trades at $70.08, up 0.33% with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional accumulation, including Focus Financial Network increasing its stake by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF provides diversified exposure to global defense stocks amid rising military spending trends.
Outlook is supported by geopolitical tensions and defense budget growth, but risks include policy shifts and valuation concerns. Analysts note SHLD's lower fees and tech focus versus peers, with a dividend of $0.19 scheduled for July 2026. Key resistance is at $70, with support at $69.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →